Correlation between Inflammation and Fibrinolysis Impairment on Central Obesity: A Study for hsCRP, PAI-1, PAP and TAFI

Winni Agustiani, Mansyur Arif, Ilhamjaya Patellongi


BACKGROUND: Inflammation in the vascular wall plays an important role in the pathogenesis of atherosclerosis. Current studies have shown that increase of systemic inflammatory marker like the acute phase component C-reactive protein (CRP) are associated with an unfavorable progression of disease and an increased risk for acute cardiovascular events. Recently, a close association of Metabolic Syndrome (MetS) with hemostatic abnormalities has been reported. Among hemostatic abnormalities, an increase in plasminogen activator inhibitor (PAI)-1, a strong inhibitor of fibrinolysis, is considered a core feature of MetS. High PAI-1 concentrations may be associated with thrombus formation, also causing cardiovascular events. Therefore, we investigated the association between markers for chronic inflammation (CRP) and the markers of fibrinolytic impairment (PAI-1, PAP, TAFI) in subjects with central obesity.

METHODS: This was a cross-sectional study in 80 male Indonesian subjects, aged 30-60 years old with central obesity, conducted from January to March 2008 in Bandung.

RESULTS: The study results showed that there was a difference of PAI-1 levels between MetS and Non-MetS group. There were significant correlations between hsCRP and PAI-1 (r=0.252, p=0.024 ), hsCRP and PAP (r=0.253, p=0.024), and also between PAI-1 and PAP (r=-0.239, p=0.033 ) respectively. But, no correlation found between hsCRP and TAFI.

CONCLUSIONS: There was correlation between inflammation and fibrinolysis impairment on central obesity. Concentrations oh hsCRP, PAI-1 and TAFI were significantly higher in MetS.

KEYWORDS: inflammation, fibrinolysis impairment, hsCRP, PAI-1, PAP, TAFI

Full Text:



Das UN. Is metabolic syndrome X an inflammatory condition? Exp Biol Med. 2002; 227: 989-97, PMID.

Tomiyama H, Koji Y, Yambe M, Motobe K, Shiina K, Gulnisa Z, et al. Elevated C-reactive protein augments increased arterial stiffness in subjects with the metabolic syndrome. Hypertension. 2005; 45: 997-1003, CrossRef.

Godsland IF, Crook D, Paroudler AJ, Stevenson JC. Hemostatic risk factor and insulin sensitivity, regional body fat distribution and the metabolic syndrome. J Clin Endocrinol Metab. 2005; 90: 190-7, CrossRef.

Anand SS, Yi Q, Gerstein H, Lonn E, Jacobs R, Vuksan V, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation. 2003; 108: 420-5, CrossRef.

Stegenga ME, Van Der Crabben SN, Levi M. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes. 2006; 55: 1807-12, CrossRef.

Sakkinen PA, Cushman M, Psaty BM, Rodriguez B, Boineau R, Kuller LH, et al. Relationship of plasmin generation to cardiovascular disease risk factor in elderly men and women. Arterioscler Thromb Vasc Biol. 1999; 19: 499-505, CrossRef.

Aso Y, Wakabayashi S, Yamamoto R, Matsumoto R, Takebayashi K, Inukai T. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes. Diabetes Care. 2005; 28: 2211-6, CrossRef.

Hryszko T, Malyszko J, Malyszko JS, Brzosko S, Pawlak K, Mysliwiec M. A possible role of thrombin-activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients. Nephrol Dial Transplant. 2001; 16: 1692-6, CrossRef.

Cabalerro AE. Endothelial dysfunction in obesity and insulin resistance : a road to diabetes and heart disease. Obes Res. 2003; 11: 1278-89, CrossRef.

Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest. 2003; 112: 1785-8, CrossRef.

Speidl WS, Zeiner A, Nikfardjam M, Geppert A, Jordanova N, Niessner A, et al. An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial brinolytic response after venous occlusion. J Am Coll Cardiol. 2005; 45: 30-4, CrossRef.

Henry M, Aubert H, Morange PE, Nanni I, Alessi MC, Tiret L, et al. Identification of polymorphisms in the promoter and the 39 region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood. 2001; 97: 2053-8, CrossRef.

Scroeder V, Kucher N, Kohler HP. Role of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with acute pulmonary embolism. Journal of Thrombosis and Haemostasis. 2003; 1: 492-3, CrossRef.

Kujawski MRF, Hoppensteadt D, Iqbal I, Demir M, Tobu M, Fareed D, Fareed J. Role of PAI-1 and TAFI in the mediation of fibrinolytic de cit in cacner patients. Journal of Clinical Oncology. 2004; 22: 9727, article.

Vague IJ, Renucci JF, Grimaux RM, Morange PE, Gouvernet J, Gourmelin Y, et al. Thrombin activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2000; 20: 2156-61, CrossRef.

Marx PF, Meijers JCM. TAFI: regulating the cross talk between coagulation and brinolyisis. J Lab Med. 2005; 29: 412-20, CrossRef.


Copyright (c) 2011 The Prodia Education and Research Institute

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


Indexed by:






The Prodia Education and Research Institute